In Brief: Visx
This article was originally published in The Gray Sheet
Executive SummaryVisx: Firm gains FDA approval of a premarket approval application supplement for use of its Star excimer laser in correcting myopic astigmatism of -0.75 to -0.4 diopters in patients with myopia of between -1 and -6 diopters. In January, the agency's Ophthalmic Devices Panel recommended that FDA approve the indication. The Santa Clara, California-based firm received an approvable letter in February ("The Gray Sheet" Feb. 17, In Brief). Per the panel's recommendation, the age limit for the new indication is raised from 18 and over to those 21 and over...
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.